Serveur d'exploration Tocilizumab - Analysis (France)

Index « Auteurs » - entrée « Jacques Morel »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Jacques Marchet < Jacques Morel < Jacques Olivier Pers  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 26.
[0-20] [0 - 20][0 - 26][20-25][20-40]
Ident.Authors (with country if any)Title
000009 (2020) Guillaume Decarriere [France] ; Thomas Barnetche [France] ; Bernard Combe [France] ; Cécile Gaujoux-Viala [France] ; Cédric Lukas [France] ; Jacques Morel [France] ; Claire Daien [France]The most appropriate conventional DMARD to combine with different advanced therapies in rheumatoid arthritis: a systematic literature review with meta-analysis.
000015 (2020) Jacques Morel [France] ; Marie Locci [France] ; Frédéric Banal [France] ; Bernard Combe [France] ; Grégoire Cormier [France] ; Maxime Dougados [France] ; René-Marc Flipo [France] ; Christian Marcelli [France] ; Thao Pham [France] ; Stéphanie Rist [France] ; Elizabeth Solau Gervais [France] ; Jean Sibilia [France] ; Cédric Lukas [France]Safety of surgery in patients with rheumatoid arthritis treated with tocilizumab: data from the French (REGistry -RoAcTEmra) Regate registry.
000050 (2019-06-12) Kedra Joanna [France] ; Philippe Dieudé [France] ; Hubert Marotte [États-Unis] ; Alexandre Lafourcade [France] ; Emilie Ducourau [France] ; Thierry Schaeverbeke [France] ; Aleth Perdriger [France] ; Martin Soubrier [France] ; Jacques Morel [France] ; Arnaud Constantin [Royaume-Uni] ; Emmanuelle Dernis [France] ; Valérie Royant [France] ; Jean-Hugues Salmon [France] ; Thao Pham [France] ; Jacques-Eric Gottenberg [France] ; Edouard Pertuiset [France] ; Maxime Dougados [France] ; Valérie Devauchelle-Pensec [France] ; Philippe Gaudin [France] ; Gregoire Cormier [France] ; Philippe Goupille [France] ; Xavier Mariette [France] ; Francis Berenbaum [France] ; Didier Alcaix [France] ; Sid Ahmed Rouidi [France] ; Jean-Marie Berthelot [France] ; Agnès Monnier [France] ; Christine Piroth [France] ; Frederic Liote [France] ; Vincent Goeb [France] ; Cécile Gaujoux-Viala [France] ; Isabelle Chary Valckenaere [France] ; David Hajage [France] ; Florence Tubach [France] ; Bruno Fautrel [France]Towards the lowest efficacious dose (toledo): results of a multicenter non-inferiority randomized open-label controlled trial assessing tocilizumab or abatacept injection spacing in rheumatoid arthritis patients in remission
000112 (2019) Jacques-Eric Gottenberg [France] ; Jacques Morel [France] ; Elodie Perrodeau [France] ; Thomas Bardin [France] ; Bernard Combe [France] ; Maxime Dougados [France] ; Rene-Marc Flipo [France] ; Alain Saraux [France] ; Thierry Schaeverbeke [France] ; Jean Sibilia [France] ; Martin Soubrier [France] ; Olivier Vittecoq [France] ; Gabriel Baron [France] ; Arnaud Constantin [France] ; Philippe Ravaud [France] ; Xavier Mariette [France]Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study
000160 (2018) Jean-Hugues Salmon ; Jeanne-Marie Perotin ; Jacques Morel [France] ; Moustapha Dramé ; Alain Cantagrel [France] ; Liana Euller Ziegler ; Philippe Ravaud [France] ; Jean Sibilia ; Isabelle Pane [France] ; Xavier Mariette ; Jacques-Eric Gottenberg [France]Serious infusion-related reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: prospective registry data.
000173 (2018) Cem Gabay [Suisse] ; Bruno Fautrel [France] ; Jürgen Rech [Allemagne] ; François Spertini [Suisse] ; Eugen Feist [Allemagne] ; Ina Kötter [Allemagne] ; Eric Hachulla [France] ; Jacques Morel [France] ; Thierry Schaeverbeke [France] ; Mohamed A. Hamidou [France] ; Thierry Martin [France] ; Bernhard Hellmich [Allemagne] ; Peter Lamprecht [Allemagne] ; Hendrik Schulze-Koops [Allemagne] ; Delphine Sophie Courvoisier [Suisse] ; Andrew Sleight [Suisse] ; Eduardo Jorge Schiffrin [Suisse]Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease
000187 (2018) William Terreaux [France] ; Claire Masson [France] ; Jean-Paul Eschard [France] ; Thomas Bardin [France] ; Arnaud Constantin [France] ; Loïc Le Dantec [France] ; Christian Marcelli [France] ; Aleth Perdriger [France] ; Claire Scotto Di Fazano [France] ; Daniel Wendling [France] ; Jean Sibilia [France] ; Jacques Morel [France] ; Jean-Hugues Salmon [France]Incidence of paradoxical reactions in patients treated with tocilizumab for rheumatoid arthritis: Data from the French registry REGATE.
000219 (2017-11-03) Jacques-Eric Gottenberg [France] ; Jacques Morel [France] ; Arnaud Constantin [Royaume-Uni] ; Thomas Bardin [France] ; Alain Cantagrel [France] ; Bernard Combe [France] ; Maxime Dougados [France] ; René-Marc Flipo [France] ; Alain Saraux [France] ; Thierry Schaeverbeke [France] ; Jean Sibilia [France] ; Martin Soubrier [France] ; Olivier Vittecoq [France] ; Gabriel Baron [France] ; Elodie Perrodeau [France] ; Philippe Ravaud [France] ; Xavier Mariette [France]Corticosteroid Sparing Effect of Non-TNF Targeted Biologics, Rituximab, Abatacept and Tocilizumab in Common Practice: Data from 3183 Patients Enrolled in the French Society of Rheumatology Registries
000220 (2017-07-14) Jacques Morel [France] ; Arnaud Constantin [France] ; Gabriel Baron [France] ; Emmanuelle Dernis [France] ; René-Marc Flipo [France] ; Stéphanie Rist [France] ; Bernard Combe [France] ; Jacques-Eric Gottenberg [France] ; Thierry Schaeverbeke [France] ; Martin Soubrier [France] ; Olivier Vittecoq [France] ; Maxime Dougados [France] ; Alain Saraux [France] ; Xavier Mariette [France] ; Philippe Ravaud [France] ; Jean Sibilia [France]Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French registry REGATE
000239 (2017) Johanna Sigaux [France] ; Florian Bailly [France] ; David Hajage [France] ; Xavier Mariette [France] ; Jacques Morel [France] ; Frédérique Gandjbakhch [France] ; Violaine Foltz [France] ; Laure Gossec [France] ; Florence Tubach [France] ; Bruno Fautrel [France]Sustainability of TNF-blocker tapering in rheumatoid arthritis over 3 years: long-term follow-up of the STRASS (Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study) randomised controlled trial
000242 (2017) Louise K. Mercer [Royaume-Uni] ; Anne C. Regierer [Allemagne] ; Xavier Mariette [France] ; William G. Dixon [Royaume-Uni] ; Eva Baecklund [Suède] ; Karin Hellgren [Suède] ; Lene Dreyer [Danemark] ; Merete Lund Hetland [Danemark] ; René Cordtz [Danemark] ; Kimme Hyrich [Royaume-Uni] ; Anja Strangfeld [Allemagne] ; Angela Zink [Allemagne] ; Helena Canhao [Portugal] ; M Victoria Hernandez [Espagne] ; Florence Tubach [France] ; Jacques-Eric Gottenberg [France] ; Jacques Morel [France] ; Jakub Zavada [République tchèque] ; Florenzo Iannone [Italie] ; Johan Askling [Suède] ; Joachim Listing [Allemagne]Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project
000245 (2017) Jacques Morel [France] ; Arnaud Constantin [France] ; Gabriel Baron [France] ; Emmanuelle Dernis ; René Marc Flipo ; Stéphanie Rist ; Bernard Combe [France] ; Jacques Eric Gottenberg [France] ; Thierry Schaeverbeke ; Martin Soubrier ; Olivier Vittecoq ; Maxime Dougados [France] ; Alain Saraux ; Xavier Mariette [France] ; Philippe Ravaud [France] ; Jean Sibilia [France]Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE.
000268 (2017) Yoann Ladner [France] ; Silvia Mas [France] ; Gaelle Coussot [France] ; Killian Bartley [France] ; Jérôme Montels [France] ; Jacques Morel [France] ; Catherine Perrin [France]Integrated microreactor for enzymatic reaction automation: An easy step toward the quality control of monoclonal antibodies.
000272 (2017) Johanna Sigaux [France] ; Moustafa Hamze [France] ; Claire Daien [France] ; Jacques Morel [France] ; Roman Krzysiek [France] ; Marc Pallardy [France] ; Bernard Maillere [France] ; Xavier Mariette [France] ; Corinne Miceli-Richard [France]Immunogenicity of tocilizumab in patients with rheumatoid arthritis.
000315 (2016) Louise K. Mercer [Royaume-Uni] ; Johan Askling [Suède] ; Pauline Raaschou [Suède] ; William G. Dixon [Royaume-Uni] ; Lene Dreyer [Danemark] ; Merete Lund Hetland [Danemark] ; Anja Strangfeld [Allemagne] ; Angela Zink [Allemagne] ; Xavier Mariette [France] ; Axel Finckh [Suisse] ; Helena Canhao [Portugal] ; Florenzo Iannone [Italie] ; Jakub Zavada [République tchèque] ; Jacques Morel [France] ; Jacques-Eric Gottenberg [France] ; Kimme L. Hyrich [Royaume-Uni] ; Joachim Listing [Allemagne]Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers
000332 (2016) Coline Faivre [France] ; Axel Patrice Villani [France] ; François Aubin [France] ; Dan Lipsker [France] ; Martine Bottaro [France] ; Jean-David Cohen [France] ; François Durupt [France] ; Géraldine Jeudy [France] ; Emilie Sbidian [France] ; Eric Toussirot [France] ; Valérie Badot [Belgique] ; Sébastien Barbarot [France] ; Sébastien Debarbieux [France] ; Emmanuel Delaporte [France] ; Guetty Goegebeur [France] ; Jacques Morel [France] ; Aude Nassif [France] ; Gérard Duru [France] ; Denis Jullien [France]Hidradenitis suppurativa (HS): An unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases.
000368 (2015) Valérie Devauchelle-Pensec [France] ; Jacques-Eric Gottenberg [France] ; Sandrine Jousse-Joulin [France] ; Jean-Marie Berthelot [France] ; Aleth Perdriger [France] ; Eric Hachulla [France] ; Pierre Yves Hatron [France] ; Xavier Puechal [France] ; Véronique Le Guern [France] ; Jean Sibilia [France] ; Laurent Chiche [France] ; Vincent Goeb [France] ; Olivier Vittecoq [France] ; Claire Larroche [France] ; Anne Laure Fauchais [France] ; Gilles Hayem [France] ; Jacques Morel [France] ; Charles Zarnitsky [France] ; Jean Jacques Dubost [France] ; Philippe Dieudé [France] ; Jacques Olivier Pers [France] ; Divi Cornec [France] ; Raphaele Seror [France] ; Xavier Mariette [France] ; Emmanuel Nowak [France] ; Alain Saraux [France]Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren’s Syndrome?
000387 (2015) Rachel Audo [France] ; Claire Daien [France] ; Laura Papon [France] ; Cédric Lukas [France] ; Olivier Vittecoq [France] ; Michael Hahne [France, Pays-Bas] ; Bernard Combe [France] ; Jacques Morel [France]Osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand as prognostic factors in rheumatoid arthritis: results from the ESPOIR cohort
000395 (2015) Claire Immediato Daïen [France] ; Sarah Gailhac [France] ; Rachel Audo [France] ; Thibault Mura [France] ; Michael Hahne [France] ; Bernard Combe [France] ; Jacques Morel [France]High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis.
000419 (2015) Alice Courties [France] ; Gilles Grateau ; Peggy Philippe ; René-Marc Flipo ; Leonardo Astudillo ; Bérengère Aubry-Rozier ; Isabelle Fabreguet ; Wafki Fahd ; Olivier Fain ; Pascal Guggenbuhl ; Eric Hachulla ; Thomas Papo ; Christophe Richez ; Jean Sibilia ; Jacques Morel ; Francis Berenbaum ; Jérémie SellamAA amyloidosis treated with tocilizumab: case series and updated literature review.
000445 (2014) Claire I. Daïen [France] ; Jacques Morel [France]Predictive Factors of Response to Biological Disease Modifying Antirheumatic Drugs: Towards Personalized Medicine

List of associated KwdEn.i

Nombre de
documents
Descripteur
20
11Humans
10Female
10Male
9Arthritis, Rheumatoid (drug therapy)
8Adult
8Middle Aged
7Aged
6Antibodies, Monoclonal, Humanized (adverse effects)
4Antibodies, Monoclonal, Humanized (therapeutic use)
4Antirheumatic Agents (therapeutic use)
4Prospective Studies
4Registries
4Risk Factors
3Adolescent
3Antibodies, Monoclonal, Humanized (administration & dosage)
3Antirheumatic Agents (adverse effects)
3Arthritis, Rheumatoid (immunology)
3France (epidemiology)
3Incidence
3Rituximab (adverse effects)
3Severity of Illness Index
3Treatment Outcome
3Tumor Necrosis Factor-alpha (antagonists & inhibitors)
2Abatacept
2Abatacept (adverse effects)
2Arthritis
2Biological Products (therapeutic use)
2Drug Eruptions (etiology)
2Follow-Up Studies
2Infusions, Intravenous
2Peptides, Cyclic (immunology)
2Retrospective Studies
2Rituximab
2tocilizumab
1Abatacept (administration & dosage)
1Abatacept (therapeutic use)
1Adalimumab
1Adalimumab (adverse effects)
1Aged, 80 and over
1Amyloid A amyloidosis
1Amyloidosis (drug therapy)
1Amyloidosis (pathology)
1Analysis of Variance
1Anaphylaxis
1Anaphylaxis (chemically induced)
1Anaphylaxis (epidemiology)
1Anti-Inflammatory Agents, Non-Steroidal (adverse effects)
1Anti-TNF
1Anti-Tumor Necrosis Factor-alpha
1Antibodies
1Antibodies, Monoclonal
1Antibodies, Monoclonal (adverse effects)
1Antibodies, Monoclonal (therapeutic use)
1Antibodies, Monoclonal, Humanized
1Antibodies, Monoclonal, Humanized (analysis)
1Antibodies, Monoclonal, Humanized (blood)
1Antibodies, Monoclonal, Murine-Derived (therapeutic use)
1Antirheumatic Agents
1Antirheumatic Agents (administration & dosage)
1Antirheumatic agent
1Arthritis (drug therapy)
1Arthritis, Rheumatoid (blood)
1Arthritis, Rheumatoid (diagnosis)
1Arthritis, Rheumatoid (epidemiology)
1Arthritis, Rheumatoid (genetics)
1Arthritis, Rheumatoid (physiopathology)
1Autoantibodies (blood)
1Automation
1B cells
1Biological Factors (therapeutic use)
1Biological Products (adverse effects)
1Biological agent
1Body Mass Index
1CD4-Positive T-Lymphocytes (immunology)
1Case-Control Studies
1Certolizumab Pegol
1Chemistry, Pharmaceutical (instrumentation)
1Chronic
1Cohort Studies
1Contraindications
1Crohn Disease (chemically induced)
1Crohn Disease (drug therapy)
1Cyclic
1Cytokines (biosynthesis)
1Drug Eruptions
1Drug Eruptions (epidemiology)
1Drug Monitoring (methods)
1Drug Monitoring (statistics & numerical data)
1Drug Resistance
1Drug Substitution
1Drug Therapy, Combination
1Drug Therapy, Combination (methods)
1Drug Therapy, Combination (statistics & numerical data)
1Drug-Related Side Effects and Adverse Reactions (epidemiology)
1Drug-Related Side Effects and Adverse Reactions (etiology)
1Electrophoresis, Capillary
1Enzyme Assays (methods)
1Enzyme-Linked Immunosorbent Assay
1Etanercept

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/France/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i -k "Jacques Morel" 
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i  \
                -Sk "Jacques Morel" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    France
   |étape=   Analysis
   |type=    indexItem
   |index=    Author.i
   |clé=    Jacques Morel
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021